Organovo Stock Forecast, Price & News

Wall Street analysts have given Organovo a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Organovo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Organovo saw a decline in short interest in the month of February. As of February 12th, there was short interest totaling 268,100 shares, a decline of 23.6% from the January 28th total of 351,000 shares. Based on an average trading volume of 385,200 shares, the days-to-cover ratio is currently 0.7 days. Approximately 3.8% of the company's stock are short sold.
View Organovo's Short Interest.

Organovo is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Organovo.

Organovo Holdings, Inc. (NASDAQ:ONVO) released its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.00). The medical research company earned $0.67 million during the quarter, compared to the consensus estimate of $0.77 million.
View Organovo's earnings history.

Organovo's stock was trading at $5.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONVO shares have increased by 105.4% and is now trading at $10.68.
View which stocks have been most impacted by COVID-19.

Organovo's stock reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split.

3 employees have rated Organovo CEO Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among Organovo's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Organovo include Checkmate Pharmaceuticals (CMPI), Eiger BioPharmaceuticals (EIGR), PDL BioPharma (PDLI), CASI Pharmaceuticals (CASI), Lineage Cell Therapeutics (LCTX), Cabaletta Bio (CABA), LogicBio Therapeutics (LOGC), Voyager Therapeutics (VYGR), Applied Genetic Technologies (AGTC), Axcella Health (AXLA), Gamida Cell (GMDA), ADMA Biologics (ADMA), INmune Bio (INMB), Fennec Pharmaceuticals (FENC) and Genfit (GNFT).
View all of ONVO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), The Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Organovo's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.36%), Jane Street Group LLC (0.23%) and Northern Trust Corp (0.22%).
View institutional ownership trends for Organovo.

ONVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Organovo or view top insider-selling stocks.

ONVO stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Northern Trust Corp.
View insider buying and selling activity for Organovo or or view top insider-buying stocks.

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ONVO stock can currently be purchased for approximately $10.68.

Organovo has a market capitalization of $76.01 million and generates $2.20 million in revenue each year.

Organovo employs 7 workers across the globe.

The official website for Organovo is www.organovo.com.

Organovo is headquartered at 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075.

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]